Physician profile
James D Gilbert
NPI 1033177126
$8,496.11
in general payments reported to CMS, 2019-2025
48 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $1,355 · 2021: $1,737 · 2022: $337 · 2023: $1,509 · 2024: $1,185 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.82 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,058.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,057.54 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $822.18 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Novo Nordisk INC | $743.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $719.95 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $558.89 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $529.60 | 2019-2022 | |
| Pfizer INC. | $522.18 | 2019-2025 | |
| Astellas Pharma US INC | $221.55 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $217.78 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.72 | 2021-2023 | Gattex |
| Amarin Pharma, INC. | $114.62 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $113.51 | 2020-2024 | Ajovy, Austedo |
| Sanofi-Aventis U.S. LLC | $105.74 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.61 | 2021-2024 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.